Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YS-ON-001 in advanced solid tumors
NCT03131765Phase 1Completed
- Sponsor
- LakeShore Biopharma Co., Ltd
- Start
- Apr 2017
- Primary completion
- Dec 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YS-ON-001 in solid tumor, breast cancer and liver cancer, sponsored by LakeShore Biopharma Co., Ltd. Primary endpoints: Safety of YS-ON-001 at 1 year, Tolerability of YS-ON-001 at 6 months and 1 more. Started Apr 2017; status: completed.
02
Drugs
YS-ON-001
03
Conditions
solid tumorbreast cancerliver cancer
Beyond the preview
Go deeper on NCT03131765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03131765.